Form 8-K - Current report:
SEC Accession No. 0001641172-25-011607
Filing Date
2025-05-20
Accepted
2025-05-20 08:00:55
Documents
14
Period of Report
2025-05-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 39368
2 EX-99.1 ex99-1.htm EX-99.1 148174
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3201
  Complete submission text file 0001641172-25-011607.txt   378309

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE prph-20250520.xsd EX-101.SCH 3026
5 XBRL LABEL FILE prph-20250520_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE prph-20250520_pre.xml EX-101.PRE 22366
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3727
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 25966195
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)